Low-energy extracorporeal shock wave ameliorates ischemic acute kidney injury in rats. 2019

Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

BACKGROUND Low-energy extracorporeal shock wave (SW) improves ventricular function in ischemic cardiomyopathy through the upregulation of vascular endothelial growth factor (VEGF). VEGF is known to play important roles in acute kidney injury (AKI), and the present study investigates the efficacy of SW for AKI by renal ischemia-reperfusion (I/R) injury. METHODS Male 8-week-old Sprague-Dawley rats were divided into the following groups: SW-treated I/R group (I/R-SW), untreated I/R group (I/R), and Sham group. To induce I/R, the left renal pedicles were clamped for 45 min. The I/R-SW group was treated with SW to both kidneys on the immediate postoperative period (day 0), days 1, 2, 7, 8, 9, 14, 15, and 16. Rats were killed on day 2 and day 20 to determine histology, renal function, and Vegf family mRNA expression. RESULTS Plasma creatinine on day 2 was significantly lower in the I/R-SW group than in the I/R group. Light microscopy revealed significantly lower tubular injury scores for the outer medulla in the I/R-SW group than in the I/R group. Podoplanin-positive lymphatic vessels were significantly increased in the left (affected side) outer medulla in the I/R-SW group on day 20. The expression levels of Vegf in the right (intact side) cortex were significantly higher in the I/R-SW group than in the I/R group on day 2. CONCLUSIONS Shock wave ameliorated renal tubular injury and renal function in AKI model, through the stimulation of Vegf family expression and lymphangiogenesis. SW may be effective as a non-invasive treatment for ischemic AKI.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D000074059 Extracorporeal Shockwave Therapy A nonsurgical treatment that uses either HIGH-ENERGY SHOCK WAVES or low energy ACOUSTIC WAVES to treat various musculoskeletal conditions (e.g., PLANTAR FASCIITIS; TENNIS ELBOW). A probe placed on the skin conducts the shock waves thereby delivering a mechanical force to the body’s tissues. Extracorporeal High-Intensity Focused Ultrasound Therapy,Extracorporeal Shock Wave Therapy,HIFU Therapy,High-Intensity Focused Ultrasound Therapy,Shock Wave Therapy,Extracorporeal High Intensity Focused Ultrasound Therapy,Extracorporeal Shockwave Therapies,HIFU Therapies,High Intensity Focused Ultrasound Therapy,Shock Wave Therapies,Shockwave Therapies, Extracorporeal,Shockwave Therapy, Extracorporeal,Therapy, Extracorporeal Shockwave,Therapy, HIFU,Therapy, Shock Wave
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular
D052250 Nitric Oxide Synthase Type III A CALCIUM-dependent, constitutively-expressed form of nitric oxide synthase found primarily in ENDOTHELIAL CELLS. ECNOS Enzyme,ENOS Enzyme,Endothelial Constitutive Nitric Oxide Synthase,Endothelial Nitric Oxide Synthase,Nitric Oxide Synthase, Type III
D058186 Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions. Acute Kidney Failure,Acute Kidney Insufficiency,Acute Renal Failure,Acute Renal Injury,Acute Renal Insufficiency,Kidney Failure, Acute,Kidney Insufficiency, Acute,Renal Failure, Acute,Renal Insufficiency, Acute,Acute Kidney Failures,Acute Kidney Injuries,Acute Kidney Insufficiencies,Acute Renal Failures,Acute Renal Injuries,Acute Renal Insufficiencies,Kidney Failures, Acute,Kidney Injuries, Acute,Kidney Injury, Acute,Kidney Insufficiencies, Acute,Renal Failures, Acute,Renal Injuries, Acute,Renal Injury, Acute,Renal Insufficiencies, Acute

Related Publications

Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
January 2019, Oxidative medicine and cellular longevity,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
January 2019, The journal of sexual medicine,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
December 2022, Scientific reports,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
July 2023, Scientific reports,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
June 2020, Experimental neurology,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
January 2003, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
November 2011, Nihon rinsho. Japanese journal of clinical medicine,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
November 1996, Renal failure,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
August 2015, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Mai Yoshida, and Takashi Nakamichi, and Takefumi Mori, and Kenta Ito, and Hiroaki Shimokawa, and Sadayoshi Ito
February 2020, Scientific reports,
Copied contents to your clipboard!